Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Parallel-Arm, Optimal Dose-Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended-Release (ER) in Japanese Subjects Treated With Around-the-Clock Opioid Analgesics for Their Moderate to Severe Chronic Malignant Tumor- Related Cancer Pain
Conditions
Interventions
Tapentadol ER
Morphine SR
Locations
22
Japan
Chiba, Japan
Hamamatsu, Japan
Ibaraki, Japan
Kanagawa, Japan
Katsushika-ku, Japan
Kobe, Japan
Start Date
August 1, 2010
Primary Completion Date
January 1, 2012
Completion Date
January 1, 2012
Last Updated
March 13, 2013
NCT07213804
NCT07159659
NCT07169851
NCT00026884
NCT06662786
NCT07191730
Lead Sponsor
Janssen Pharmaceutical K.K.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions